EL7.AI
StocksMediumUpdated•Originally published 13 April 2026•Updated 14 April 2026•
1 min read

ANI Pharmaceuticals Launches Generic Carbatrol in US Market

Key Facts

1ANI Pharmaceuticals launched Carbamazepine Extended-Release Capsules, a generic version of Carbatrol.
2The product targets a U.S. market with approximately $65 million in annual sales.
3The drug is available in 100 mg, 200 mg, and 300 mg strengths in a limited-competition segment.

ANI Pharmaceuticals (Nasdaq: ANIP), headquartered in Princeton, N.J., officially launched its Carbamazepine Extended-Release Capsules on April 13, 2026. As a generic equivalent to Carbatrol, the product is available in 100 mg, 200 mg, and 300 mg strengths to treat epilepsy and bipolar disorder. This launch targets a U.S. market segment with annual sales of approximately $65 million, according to data from IQVIA. By entering this niche market, ANI Pharmaceuticals aims to capitalize on a segment characterized by limited competition. The move aligns with the company's strategy to expand its generics portfolio and drive sustainable revenue growth. Analysts expect a positive contribution to financial results, though the impact remains moderate relative to the total market size.